BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30221907)

  • 21. Prediction of treatment response to ¹³¹I therapy by diffuse hepatic uptake intensity on post-therapy whole-body scan in patients with distant metastases of differentiated thyroid cancer.
    Jun S; Lee JJ; Park SH; Kim TY; Kim WB; Shong YK; Ryu JS
    Ann Nucl Med; 2015 Aug; 29(7):603-12. PubMed ID: 25980591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment.
    Pace L; Klain M; Albanese C; Salvatore B; Storto G; Soricelli A; Salvatore M
    Eur J Nucl Med Mol Imaging; 2006 Feb; 33(2):179-83. PubMed ID: 16205897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
    Lind P; Gallowitsch HJ
    Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 123I isotope as a diagnostic agent in the follow-up of patients with differentiated thyroid cancer: comparison with post 131I therapy whole body scanning.
    Alzahrani AS; Bakheet S; Al Mandil M; Al-Hajjaj A; Almahfouz A; Al Haj A
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5294-300. PubMed ID: 11701695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The value of serum thyreoglobulin levels and whole body (I-131) scintigraphy in the follow-up of the thyroid cancer patients after thyroidectomy.
    Kucukalić-Selimović E; Alagić J; Valjevac A; Hadzović-Dzuvo A; Begić A; Beslić N
    Coll Antropol; 2012 Nov; 36 Suppl 2():67-71. PubMed ID: 23397758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Iodine-131 SPET/CT and 18F-FDG PET/CT for the identification and localization of mediastinal lymph node metastases from differentiated thyroid carcinoma.
    Xu YH; Shen CT; Xue YL; Qiu ZL; Luo QY
    Hell J Nucl Med; 2013; 16(3):199-203. PubMed ID: 24251307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
    Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
    J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of Differentiated Thyroid Cancer and Recurrent Laryngeal Nerve Function with 131 Iodine Based on Positron Emission Tomography/Computed Tomography Image Segmentation Algorithm.
    Zhong Y; He J; Zhang C; Ardlee B
    World Neurosurg; 2021 May; 149():428-435. PubMed ID: 33166689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Completion total thyroidectomy in children with thyroid cancer secondary to the Chernobyl accident.
    Miccoli P; Antonelli A; Spinelli C; Ferdeghini M; Fallahi P; Baschieri L
    Arch Surg; 1998 Jan; 133(1):89-93. PubMed ID: 9438766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The early detection of metastatic differentiated thyroid cancer using 131I total body scan and treatment with 131I].
    Ikekubo K; Hino M; Ito H; Yamaguchi H; Saiki Y; Ui K; Tominaga E; Nakanishi M; Kawai J; Koh T
    Kaku Igaku; 1991 Mar; 28(3):247-59. PubMed ID: 1904509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
    Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of subcentimeter metastatic cervical lymph node by 18F-FDG PET/CT in patients with well-differentiated thyroid carcinoma and high serum thyroglobulin but negative 131I whole-body scan.
    Kunawudhi A; Pak-art R; Keelawat S; Tepmongkol S
    Clin Nucl Med; 2012 Jun; 37(6):561-7. PubMed ID: 22614187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lithium as an adjuvant in the postoperative ablation of remnant tissue in low-risk thyroid carcinoma.
    Yamazaki CA; Padovani RP; Biscolla RP; Ikejiri ES; Marchetti RR; Castiglioni ML; Matsumura LK; Maciel RM; Furlanetto RP
    Thyroid; 2012 Oct; 22(10):1002-6. PubMed ID: 22953991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?
    Salvatori M; Perotti G; Rufini V; Maussier ML; Dottorini M
    Clin Endocrinol (Oxf); 2004 Dec; 61(6):704-10. PubMed ID: 15579184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
    Sergieva S; Hadjieva T; Doldurova M; Stefanova S; Dudov A
    J BUON; 2006; 11(4):511-8. PubMed ID: 17309186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of positron emission tomography scanning in patients with radioactive iodine scan-negative, recurrent differentiated thyroid cancer.
    Roberts M; Maghami E; Kandeel F; Yamauchi D; Ellenhorn HL; Ellenhorn JD
    Am Surg; 2007 Oct; 73(10):1052-6. PubMed ID: 17983080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 18F-FDG-PET/CT in Patients Affected by Differentiated Thyroid Carcinoma with Positive Thyroglobulin Level and Negative 131I Whole Body Scan. It's Value Confirmed by a Bicentric Experience.
    Bertagna F; Albano D; Bosio G; Piccardo A; Dib B; Giubbini R
    Curr Radiopharm; 2016; 9(3):228-234. PubMed ID: 27210819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer.
    Lima N; Cavaliere H; Tomimori E; Knobel M; Medeiros-Neto G
    J Endocrinol Invest; 2002 Feb; 25(2):110-5. PubMed ID: 11929080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm?
    Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
    Nuklearmedizin; 1998 Jan; 37(1):12-7. PubMed ID: 9467164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 18F-FDG-PET in the follow-up of thyroid cancer.
    Lind P; Kresnik E; Kumnig G; Gallowitsch HJ; Igerc I; Matschnig S; Gomez I
    Acta Med Austriaca; 2003; 30(1):17-21. PubMed ID: 12558561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.